InterMune Inc. Presents at UBS Global Healthcare Conference, May-22-2013 12:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: John C. Hodgman, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

InterMune Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported Esbriet(R) (pirfenidone) revenue of $10.5 million, compared with $4.9 million of Esbriet revenue in the same quarter a year earlier. Net loss was $49.9 million or $0.64 per share compared with a net loss of $46.6 million or $0.72 per share in the first quarter of 2012. Net loss was $49.9 million or $0.64 per share compared with a net loss of $46.6 million or $0.72 per share in the first quarter of 2012. Loss from operations was $47.7 million compared to $45.5 million reported a year ago. Loss from continuing operations before income taxes was $49.7 million compared to $48.5 million reported a year ago. Interest income was $0.137 million against $0.145 million a year ago. Loss from continuing operations, net of taxes was $50.1 million against $48.34 million a year ago. The company reiterated its financial guidance as announced on January 3, 2013 for the year 2013. The company's Esbriet revenue currently projected to be in a range of $40 to $70 million. This revenue guidance is in two layers. The first layer of guidance is for the projected revenue in the range of $40 million to $55 million in countries where Esbriet is currently launched. These are Germany, France, seven mid-sized European countries and Canada. The second layer of guidance is for zero to $15 million in countries where Esbriet is not yet launched. At this time, the countries in this layer of guidance are: Italy, where expect to launch by mid-June; England, where expect to launch by mid-August; Spain, on which the company plans to provide an update on reimbursement status in the fourth quarter of 2013; and three mid-sized countries of Finland where expect to launch in June; Ireland, where pricing and reimbursement procedures is expected to conclude in June, and if terms are acceptable, a launch could occur in the third quarter; and lastly, the Netherlands, in which the company expects to provide an update in the fourth quarter of 2013. R&D expense currently anticipated to be in a range of $100 to $120 million; total operating expenses (R&D and SG&A): currently anticipated to be in a range of $245 to $285 million.

InterMune Inc., Q1 2013 Earnings Call, Apr 24, 2013